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Protein tyrosine kinases catalyze the transfer of phosphate in
ATP to tyrosine residues in cellular substrates. They regulate
intracellular signaling pathways mediating cell proliferation, dif-
ferentiation, migration, metabolism, survival, and multicellular
communication.Tyrosine phosphorylation of proteins is rare and
tightly regulated in quiescent cells, but abundant in rapidly pro-
liferating or transformed cells. Intramolecular control of tyrosine
kinases involves autoinhibitory mechanisms that safeguard
against inappropriate or aberrant catalytic activity. Signaling
pathways regulated by protein tyrosine kinases are the frequent
target of somatic mutations, leading to a significant fraction of
human cancers. Of the >100 dominant oncogenes known to
date, many encode receptor and cytoplasmic protein tyrosine
kinases known to be mutated and/or overexpressed in human
cancers (Blume-Jensen and Hunter, 2001). Broad-spectrum
kinase inhibitors like genistein and herbimycin have been
shown to inhibit growth of cancer cells expressing activating
tyrosine kinases, supporting a causal role for these enzymes in
transformation. In this commentary, we will focus on Abl, c-Kit,
HER2/neu (erbB2), and EGFR kinase inhibitors and critically
address their therapeutic targeting in human neoplasia. The
same arguments relevant to these molecules apply to serine-
threonine kinase inhibitors, which are also included in the
discussion.
Molecular target selection and implications for Phase I
studies
Some general conditions should be considered prior to selecting
a tyrosine kinase as a therapeutic target in cancer. It should be
causally involved in experimental tumor progression and be
identifiable in diagnostic tumor tissue. It should not have a critical
role in normal postnatal or adult physiology, thus providing an
exploitable “therapeutic window.” Finally, basic structure/function
determinants are desirable in order to develop mechanism-
based inhibitors. The potential dependence of tumors on tyro-
sine kinase function over that of normal tissues raises several
issues for their clinical development. First, these drugs are less
toxic and better tolerated than conventional chemotherapy and
are, therefore, potentially deliverable over a prolonged time.
Second, the optimal biological dose (OBD) at which they modu-
late their molecular target may not match their maximally tolerat-
ed dose (MTD). Third, the kinase-dependent tumors likely to
derive clinical benefit from a specific molecular inhibitor are not
frequently recognizable.
The clinical development of imatinib, which inhibits the Abl,
c-Kit, and PDGFR tyrosine kinases (Buchdunger et al., 2000), is
a good example of how the traditional phase I, II, and III testing
of kinase inhibitors does not fit the mainstream development
process of anticancer chemotherapy. In the phase I (toxicity)
trial of imatinib, few dose escalations were necessary prior to
signs of clinical activity in patients with CML. In this trial, inhibi-
tion of both leukemic cells and Abl kinase activity correlated
with a clinically active dose of imatinib (Druker et al., 2001b),
which is now FDA-approved, having never reached an MTD.
Another example is the phase I testing of the EGFR inhibitor
gefitinib (Iressa, ZD1839). An MTD ≥700 mg/day was defined
by severe rash and diarrhea (Baselga et al., 2002). However,
pharmacodynamic studies in skin biopsies showed evidence of
EGFR inactivation at doses ≥150 mg/day, well below the MTD
(Albanell et al., 2002). Supported by these data, a phase II (effi-
cacy) study randomized patients with advanced non-small-cell
lung cancer (NSCLC) to 250 versus 500 mg/day of gefitinib.
Response rate and symptom improvement were equal in both
arms, but more adverse reactions were observed in patients
receiving 500 mg/day (Fukuoka et al., 2003). Further, other tri-
als with EGFR antibodies and small molecule kinase inhibitors
have shown simultaneous inhibition of receptor phosphorylation
in both skin and cancer cells (J. Baselga et al., 2003, Proc. Am.
Soc. Clin. Oncol., abstract; J. Tabernero et al., 2003, Proc. Am.
Soc. Clin. Oncol., abstract). Interestingly, the competing EGFR
kinase inhibitor erlotinib (OSI-774, Tarceva) has been devel-
oped at its MTD. A recent phase III study of erlotinib given at its
MTD versus best supportive care in advanced NSCLC showed
improvement in survival in patients treated with the former
(h t t p : / /www.gene. com/gene /news /p ress - re l eases /
display.do?method=detail&id=7387). Moreover, results from
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phase II studies with EGFR inhibitors suggest that patients who
develop a severe drug-induced rash exhibit longer survival
(Perez-Soler, 2003). This last observation and the phase III
study of erlotinib will prolong the debate as to whether signal-
ing inhibitors should be developed clinically at their MTD or at
their OBD.
Knowledge of the molecular or cellular target of a signaling
inhibitor provides additional experimental endpoints that can
lead the phase I dose-defining process. For example, inactiva-
tion of ribosomal protein S6 kinase (p70S6K) in peripheral
blood mononuclear cells (PBMCs) was used to define biochem-
ically effective doses of inhibitors of the mammalian target of
rapamycin (mTOR) (Boulay et al., 2004). TOR is a serine-threo-
nine kinase involved in response to nutrients and growth factors
that activates p70S6K. Dynamic contrast-enhanced magnetic
resonance imaging (DCE-MRI) has been utilized to assess
tumor permeability and vascularity in patients treated with the
VEGFR kinase inhibitor PTK787 (Morgan et al., 2003). The cor-
relation between this measurement and clinical activity helped
determine the OBD for PTK787, supporting the use of function-
al imaging for the definition of phase II doses. Finally, in trans-
genic prostate tumors that overexpress active Akt1, there is
upregulation of genes encoding most glycoytic enzymes.
Treatment of these with mTOR inhibitors downregulates RNAs
for all theseenzymes (Majumder et al. 2004), suggesting that
positron  emission tomography (PET) that uses labeled fluo-
rodeoxyglucose as a tracer can be utilized to define biologically
effective doses of PI3K-Akt-TOR pathway inhibitors.
Imatinib (STI-571, Gleevec)
Imatinib is a small molecule that reversibly competes with ATP
for binding to the kinase domain of the PDGFR, c-Kit, and Abl
tyrosine kinases (Buchdunger et al., 2000). Phase I and II trials
were conducted in patients with chronic phase CML, a pluripo-
tent stem cell disorder characterized by the t(9,22) Philadelphia
(Phi+) chromosome translocation.This translocation results in a
fusion of Abl to the Bcr gene, resulting in activation of the Abl
tyrosine kinase. In addition to Bcr-Abl, late phase CML contains
multiple other molecular and cytogenetic abnormalities.
Treatment with imatinib results in blockade of the catalytic activ-
ity of Abl and induces major hematologic remissions, with
50%–70% of patients having no evidence of Phi+ chromosome
in the bone marrow after 3–6 months of therapy (Sawyers,
2003). In patients in blast crisis CML, imatinib also exhibits sig-
nificant clinical activity, but responses are short-lived due to the
expansion of drug-resistant CML cells (Druker et al., 2001a).
Bcr-Abl gene amplification and mutations in the Abl kinase
domain have been identified in patients with imatinib-resistant
CML or Phi+ acute lymphoblastic leukemia (ALL) (Gorre et al.,
2001). These mutations impede the binding of imatinib to the
ATP pocket in Abl (Shah et al., 2002).These studies confirm the
central pathogenic role of Bcr-Abl and have led to the identifica-
tion of second-line inhibitors. These include dual Src/Abl kinase
inhibitors capable of binding the ATP site in mutant Abl alleles
and drugs that downregulate the Abl, protein such as 17-ally-
laminogeldanamycin (17-AAG) (Gorre et al., 2002).
The molecular “promiscuity” of imatinib has expanded its
repertoire of tumor targets. Imatinib has shown remarkable
activity against gastrointestinal stromal tumors (GISTs) contain-
ing activating mutations in the c-Kit tyrosine kinase. The highest
activity was seen in GISTs with mutations at exons 9 and 11 of
the Kit gene, with low activity in GISTs expressing wild-type Kit
(Heinrich et al., 2003a). Interestingly, 35% of GISTs with wild-
type Kit have intragenic mutations in the PDGFRA gene, result-
ing in constitutively active PDGFRα (Heinrich et al., 2003b),
potentially explaining the clinical responses to imatinib in this
cohort. Imatinib also exhibits robust activity against other syn-
dromes associated with PDGFR alterations. These include
chronic myelomonocytic leukemia (CMML) expressing the con-
stitutively active TEL-PDGFRβ fusion tyrosine kinase (Apperley
et al., 2002); hypereosinophilic syndrome, which contains the
FIP1-L1-PDGFRα fusion protein (Cools et al., 2003); and a type
of sarcoma called dermatofibrosarcoma protuberans, in which a
t(17,22) chromosomal translocation leads to constitutive PDGF
ligand production (Rubin et al., 2002). These data imply that
activating mutations in genes encoding the molecular targets of
imatinib are reliable markers of “kinase dependence” and, thus,
predict for the strong clinical activity observed in single-agent
trials.
Trastuzumab (Herceptin)
Trastuzumab is a humanized IgG1 which binds to a juxtamem-
brane region in the HER2/neu (erbB2) receptor. HER2 is a
member of the HER (erbB) family of transmembrane tyrosine
kinases, which also includes the EGFR (HER1, erbB1), HER3
(erbB3), and HER4 (erbB4). Except for HER2, binding of recep-
tor-specific ligands to the ectodomain of EGFR, HER3, and
HER4 results in the formation of homodimeric and heterodimer-
ic complexes, to which HER2 is recruited as a preferred partner
(Yarden and Sliwkowski, 2001). HER2 is unable to directly inter-
act with erbB ligands but can potently enhance signaling by
HER2-containing heterodimers and/or increase the binding
affinity of ligands to EGFR and HER3/4. Enhanced levels of
HER2 are associated with mammary epithelial cell transforma-
tion and shorter survival in patients with breast cancer (Ross
and Fletcher, 1998). Approximately 25% of invasive breast can-
cers exhibit HER2 gene amplification (Slamon et al., 1989). The
rate of HER2 gene amplification or protein overexpression in
ductal carcinoma in situ (DCIS) is the same or higher than in
invasive cancers (Glockner et al., 2001), suggesting a patho-
genic role for HER2 in the initiation of mammary carcinoma.
In preclinical studies, trastuzumab blocked growth of HER2-
overexpresssing cells, but not cells with low receptor levels
(Lewis et al., 1993). Its cellular mechanisms of action have been
reviewed elsewhere, but also include inhibition of HER2 associ-
ation with erbB coreceptors resulting in blockade of HER2
kinase activity (Yakes et al., 2002). Despite high controversy,
the initial phase I and II studies were limited to patients with
chemotherapy-refractory breast cancers, with high HER2 levels
showing a response rate of approximately 20% (Cobleigh et al.,
1999). Subsequently, Vogel et al. reported impressive objective
response and clinical benefit rates of 35% and 48%, respective-
ly, in patients treated with trastuzumab alone (Vogel et al.,
2002). Slamon et al. reported a 25% improvement in survival in
patients treated with trastuzumab plus chemotherapy versus
chemotherapy alone (Slamon et al., 2001). In these studies, the
above-mentioned benefit conferred by trastuzumab was limited
to HER2-overexpressing cancers.Therefore, high HER2 protein
levels accurately predict good odds of response to trastuzumab,
which in 1998 was approved by the FDA for use in HER2-overx-
pressing breast cancer. The single-agent activity of this drug in
metastatic breast cancers also suggests that even late, geneti-
cally complex mammary tumors remain HER2-dependent. We
should emphasize that, had the pivotal trials with trastuzumab
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been conducted in unselected patients, its activity would have
been easily missed, thus threatening its approval by the FDA.
The high likelihood of a similar risk in the development of other
tyrosine kinase inhibitors cannot be underscored.
Anti-EGF receptor therapies
The success with imatinib and trastuzumab should be com-
pared with results obtained with anti-EGFR agents (Figure 1).
Trials with EGFR tyrosine kinase inhibitors in NSCLC have
shown overall modest clinical activity, with higher response
rates in women, nonsmokers, and patients with adenocarcino-
ma (Fukuoka et al., 2003; Kris et al., 2003). A detectable EGFR
level in tumors was not required for study entry, in part because
preclinical studies with EGFR inhibitors had demonstrated that
receptor content is not a predictor of receptor utilization and
hence response to treatment. In any case, no apparent
attempts were made at minimally defining an EGFR-dependent
population up front. Subsequently, in large phase III trials of
chemotherapy ± gefitinib in NSCLC, the combination failed to
improve overall survival over chemotherapy alone (Giaccone et
al., 2004; Herbst et al., 2004). Similarly, the EGFR antibody
cetuximab (C225, Erbitux), which inhibits receptor tyrosine
kinase activity by blocking ligand-induced activation (Fan et al.,
1994), failed to improve the efficacy of cisplatin-based
chemotherapy over chemotherapy alone in patients with head
and neck squamous cancers (B. Burtness et al., 2002, Proc.
Am. Soc. Clin. Oncol., abstract).
Unlike Bcr-Abl, c-Kit, and HER2, there is little evidence to
support a major pathogenic role for the wild-type EGFR in
epithelial neoplasms. Therefore, the lack of selection of tumors
with some evidence of EGFR-dependence is a viable explana-
tion for the overall modest activity of gefitinib. Recent reports
support this point further. First, approximately 20% of patients
with high-grade CNS gliomas respond to the EGFR inhibitor
erlotinib (M. Prados et al., 2003, Proc. Am. Soc. Clin. Oncol.,
abstract). About 40% of gliomas express the variant III (vIII)
EGFR, in which an in-frame deletion in the extracellular domain
results in a constitutively active mutant receptor that engages a
broader spectrum of signal transducers than the wild-type
EGFR (Antonyak et al., 1998). Determining the status of the
EGFR gene in these gliomas, the ability of erlotinib to cross the
blood-brain barrier, and the confounding effect of antiseizure
medications taken by these patients will be required for the
proper interpretation of these results. Second, two groups
recently reported somatic activating mutations in the EGFR
gene in NSCLC that exhibited durable responses to gefitinib.
The mutations were either short in-frame deletions or amino
acid substitutions clustered around the ATP binding pocket of
the receptor tyrosine kinase domain. They were more frequent
in adenocarcinoma than in other histological types of NSCLC in
women and in Japanese patients (Lynch et al., 2004; Paez et
al., 2004). In one of these studies, there was a suggestion that
the mutant receptors were hyperresponsive to ligands, implying
they confer a gain of function and, hence, EGFR dependence.
A phase III trial of erlotinib versus best supportive care in
advanced NSCLC recently showed improved survival in treated
patients (http://www.gene.com/gene/news/press-releases/
display.do?method=detail&id=7387). It remains to be deter-
mined if the benefit from erlotinib in this trial, which was pow-
ered to achieve a 33% improvement in survival, is limited to
patients with activating EGFR mutations. At this point, it is
unknown if durable responses in the low proportion of tumors
bearing EGFR mutations can account for the improvement in
overall survival. One implication from these cumulative data is
that the enrollment of unselected patients into trials with EGFR
inhibitors needs to be revisited in order to identify a cohort of
EGFR-dependent tumors against which kinase inhibitors might
exhibit clinical activity.
A strategy for patient selection into Phase II trials with
kinase inhibitors
One strategy to address this issue of patient selection consists
of the administration of a signaling inhibitor to patients with
operable cancer immediately before definitive surgery. This
presurgical approach, which can be applied to anatomically
accessible cancers (i.e., breast, head and neck, colorectal), has
been used extensively in breast cancer. Several studies have
shown that ≤14 days of therapy with tamoxifen results in marked
reduction of breast cancer proliferation as measured by Ki67
immunohistochemistry (IHC). Drug-induced inhibition of prolif-
eration was limited to ER+ tumors (Assersohn et al., 2003), sug-
gesting that this approach could have identified the ER as the
molecular signature predictive of good odds of response to
tamoxifen. This approach would also have identified ER-nega-
tive tumors as unresponsive and, therefore, point to their exclu-
sion from phase II studies with tamoxifen. Clearly, inclusion of
ER− tumors into efficacy studies would have diluted the net sig-
nal of clinical activity of the antiestrogen.
Other more recent studies suggest that measurement of
drug-induced cellular activity in situ after a short time can pre-
dict clinical outcome. Chang et al. (2003, Breast Cancer Res.
Treat., Suppl. 1, abstract) treated locally advanced HER2-over-
expressing breast cancers with weekly trastuzumab followed by
the addition of docetaxel after week 3. Significant tumor regres-
sions at 3 weeks correlated with a 2-fold increase in tumor cell
apoptosis, as measured by cleaved caspase 3 in a biopsy
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Figure 1. Clinical response rates in GIST treated with imatinib and NSCLC
treated with gefitinib
There is a high response in GIST that express c-Kit with activating mutations
in exons 9 and 11. The low response rate in GIST expressing wild-type Kit
matches that seen in NSCLC in the IDEAL 1 and 2 single agent trials with
gefitinib. The response rate in NSCLC to gefitinib approximates the recently
reported EGFR mutation rate in this disease. Up to 35% of GISTs with wild-
type Kit contain intragenic PDGFRα activating mutations, suggesting that
in these tumors, the inhibition of the PDGFR might explain the clinical activ-
ity of imatinib. CR, complete response; PR, partial response.
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obtained on day 8 after start of therapy. Further, the IMPACT
trial randomized women with ER+ breast cancers to 12 weeks
of neoadjuvant anastrozole, tamoxifen, or the combination. In a
core biopsy obtained after 2 weeks of therapy, a statistically
superior inhibition in Ki67 IHC was observed in tumors treated
with anastrozole compared to the other two arms. Interestingly,
this result predicted for a better efficacy of anastrozole in per-
mitting the use of breast-conserving surgery (M. Dowsett et al.,
2003, Breast Cancer Res.Treat., Suppl. 1, abstract).The results
of IMPACT have additional implications for the design of phase
III studies. For example, the ATAC adjuvant trial randomized
>9,000 breast cancer patients to the same 3 arms but required
33 months of follow-up to reveal that anastrozole was more
effective in prolonging disease-free survival (Baum et al., 2002).
Based on these data, we propose that had the less expensive
and shorter IMPACT trial been done first, the results of this
study could have streamlined the ATAC trial by avoiding the
combination arm, thus saving significant patients’ time and cost.
In an ongoing trial (CLA) that aims at identifying mammary
tumors with EGFR dependence, patients with newly diagnosed,
operable breast cancer are treated for 7–14 days with the EGFR
inhibitor erlotinib from the time of a baseline core biopsy until
definitive surgery. Following surgery, the patients are subjected
to the current standard of radiation, chemotherapy, and/or hor-
monal therapy. A flow diagram of such trial design is shown in
Figure 2. Drug-induced inhibition of phospho-EGFR (or another
marker of signaling pathway activation) will provide molecular
evidence of target inactivation. Next, by focusing on the tumors
in which the inhibitor induces an antiproliferative and/or a pro-
apoptotic effect, it would be possible to determine a threshold
level of receptors, or perhaps another molecular conventional
marker(s), that correlates with cellular activity. Since all patients
will be subjected to an operation as part of their standard of
care, in situ cellular response data should be available in 100%
of subjects enrolled. Data from this type of exploratory trial can
generate a tumor profile that should assist the identification and
enrollment of patients into subsequent efficacy trials with EGFR
inhibitors. One plausible outcome of this study is treatment-
induced loss of P-EGFR without evidence of cellular activity (as
measured by Ki67 and/or TUNEL). Such negative results would
anticipate lack of activity of EGFR inhibitors and, therefore, sug-
gest that phase II trials with single-agent EGFR inhibitors in
breast cancer are unwarranted. This would allow for the alloca-
tion of research resources to potentially more productive
venues within the large anticancer portfolio. A similar approach
can be used with other kinase inhibitors for which there is no
clear molecular profile or kinase mutation to recognize kinase-
dependent cancers. Perhaps more importantly, this approach
could exclude patients in whom these drugs are unlikely to pro-
duce any clinical benefit.
Kinase dependence in other tumor types:Therapeutic
implications
Genome sequencing approaches across tumor types has iden-
tified additional activating mutations suggestive of kinase
dependence. These include B-Raf mutations in melanoma
(Davies et al., 2002) and Flt3 receptor mutations in one-third of
AML and a smaller group of ALL (Nakao et al., 1996). Samuels
et al. identified somatic mutations in the PI3KCA gene, which
encodes the p110α catalytic subunit of PI3K, in a diverse cohort
of colon, brain, gastric, breast, and lung cancers (Samuels et
al., 2004). The positions of the mutations within PI3KCA sug-
gest that they may increase the enzyme’s catalytic activity. The
same group reported point mutations in the KDR gene, which
encodes VEGFR2 (Bardelli et al., 2003). Although the function-
al consequences of KDR mutations are unclear, this result rais-
es the possibility that the clinical activity of anti-VEGF agents
and VEGFR kinase inhibitors in colorectal cancer (H. Hurwitz et
al., 2003, Proc. Am. Soc. Clin. Oncol., abstract; Morgan et al.,
2003) could be explained by inhibition of ligand-activated
mutant KDR (VEGFR) in tumor cells.
In other cases, kinase dependence may not be associated
with kinase mutation. For example, the VEGF antibody
Bevacizumab (Avastin) significantly delays progression of
metastatic renal cancers (Yang et al., 2003). Interestingly, 70%
of nonhereditary renal cancers contain deletions or inactivating
mutations of the von Hippel Lindau (VHL) gene, whose product
encodes the ubiquitin ligase for hypoxia-inducible factor (HIF).
Consequently, VHL mutant tumors overproduce HIF and the
transcriptional targets of HIF such as PDGF, TGFα, TGFβ, and
erythropoietin (George and Kaelin, 2003). Thus, the overpro-
duction of VEGF in renal cancer indicates VEGFR kinase
dependence as supported by the efficacy of anti-VEGF therapy.
Based on the multiple HIF targets, we speculate that combina-
tions of inhibitors of VEGFR, EGFR, PDGFR, and TGFβ signal-
ing may have synergistic antitumor activity in VHL mutant
cancers.
Finally, mutations in the PTEN tumor suppressor gene also
result in kinase dependence. PTEN selectively dephosphory-
lates PI3,4,5P3, thus negatively regulating the product of PI3K.
Loss of PTEN in a wide group of cancers (Vivanco and
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Figure 2. Exploratory trial design for molecular target validation and identi-
fication of predictive markers of response to EGFR inhibitors
Patients with operable breast cancer and patients who refuse neoadju-
vant chemotherapy will be treated with the established phase II dose of
an oral EGFR inhibitor for a period of ≤2 weeks. Ki67 and TUNEL will be
determined in both a diagnostic core biopsy and surgical specimen to
assess if there is a reduction of tumor cell proliferation and/or increase in
apoptosis. A ≥75% reduction in Ki67+ cells by IHC and/or a ≥2-fold increase
in apoptosis as measured by TUNEL will be then correlated with the indi-
cated markers, all measured in paraffin-embedded tumor sections. By
comparing endpoints in pre- and posttherapy specimens in this treat-
ment-naive, in vivo model, a predictive marker(s) for response to EGFR
inhibitors can be developed. This same marker(s) can be then used to
select patients into targeted phase II trials that will address the clinical
effect of these inhibitors. Inhibition of P-EGFR (or other marker of signaling
pathway activation) in posttherapy sections is required to control for evi-
dence of target inactivation.
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Sawyers, 2002) results in increased PI3K activity and overde-
pendence on this pathway, as PTEN null cells exhibit supersen-
sitivity to mTOR and PI3K inhibitors (Neshat et al., 2001).
Based on these studies, PTEN alterations are being used to
select patients into trials with mTOR inhibitors.
Therapeutic resistance
An advantage of targeting pathogenic tyrosine kinases is that
cancer cells, as a result of treatment, may modify them or their
signaling partners and thus provide molecular clues about ther-
apeutic resistance which can be used for discovery of 2nd-line
strategies. One example of the strength of this approach is the
demonstration that dual Abl/Src inhibitors can bind the activa-
tion loop of Abl in its closed or open conformation (Nagar et al.,
2002), thus explaining their ability to inhibit CML cells express-
ing imatinib-resistant Abl mutations (Huron et al., 2003). In
hypereosinophilic syndrome expressing the FIP1L1-PDGFRα
fusion protein, acquisition of a T674I mutation is causally asso-
ciated with the emergence of imatinib resistance (Cools et al.,
2003). Knowledge of the structural effects of this substitution in
the ATP binding pocket of the PDGFRα tyrosine kinase should
help the identification of inhibitors of the resistant mutant.
In the case of trastuzumab, there are no published studies
yet on primary tumors that escape antibody-induced HER2
blockade. A comprehensive effort in which tumors are rebiop-
sied at the time of escape will be required to gain insights as to
whether this resistance is HER2-dependent or -independent
and/or if it is secondary to novel ERBB2 mutations. Drugs that
might be useful in the setting of HER2-dependent resistance to
trastuzumab include small molecule inhibitors of the HER2
kinase such as GW572016 (Rusnak et al., 2001), the Hsp90
inhibitor 17-AAG, which can downregulate HER2 protein levels
(Basso et al., 2002), and the humanized IgG pertuzumab (2C4).
2C4 binds to an epitope different to that recognized by
trastuzumab and sterically hinders the recruitment of HER2 into
heregulin-induced HER2/3 heterodimers in both low and high
HER2-expressing cells (Agus et al., 2002).
Conclusions
The clinical activity of imatinib and trastuzumab has proven the
utility of targeting pathogenic tyrosine kinases responsible for
the progression of specific cancers. On the other hand, the
overall modest activity of anti-EGFR therapies suggests the
need of methods that identify EGFR-dependent tumors that can
be integrated into the clinical trial process. The data presented
clearly indicate that kinase dependence and patient selection
are central to the rational and successful development of thera-
peutic tyrosine kinase inhibitors. This development will require
novel approaches, such as the prospective selection of
patients/tumors with activating mutant kinases into trials with
specific inhibitors. A second approach would be exploratory tri-
als that examine pharmacodynamic cellular and molecular
changes in tumor tissues upon inhibition of tyrosine kinases
and/or a clinical trial research plan that maximizes the molecu-
lar information obtained in diagnostic tumor material.
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